z-logo
Premium
Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice
Author(s) -
Hul Matthias,
Lupu Florea,
Dresselaers Tom,
Buyse Johan,
Lijnen H Roger
Publication year - 2012
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2012.05714.x
Subject(s) - adipose tissue , endocrinology , medicine , matrix metalloproteinase , gelatinase , chemistry , extracellular matrix , tissue inhibitor of metalloproteinase , adipose tissue macrophages , white adipose tissue , biology , biochemistry
Summary Because the development of adipose tissue involves remodelling of the extracellular matrix ( ECM ), which requires matrix metalloproteinase ( MMP ) activity, we examined whether MMP inhibitors may have the potential to affect adipose tissue mass in obese mice. Administration of the relatively gelatinase‐specific MMP inhibitor tolylsam (( R )‐3‐methyl‐2‐[4‐(3‐p‐tolyl‐[1,2,4]oxadiazol‐5‐yl)‐benzenesulphonylamino]‐butyric acid; 100 mg/kg per day) for 7 weeks to obese wild‐type mice on a high‐fat diet resulted in significantly lower bodyweight ( P  < 0.05), lower subcutaneous ( SC ) and gonadal ( GON ) adipose tissue mass (both P  < 0.05) and smaller adipocytes in both SC ( P  < 0.005) and GON ( P  < 0.0005) adipose tissues. Magnetic resonance imaging confirmed a lower total body fat content in tolylsam‐treated mice ( P  < 0.0005). In addition, tolylsam treatment of wild‐type mice was associated with a marked enhancement in metabolic rate. Electron microscopy analysis of tissue sections at the end of the 7 week feeding period revealed significantly higher collagen accumulation in the ECM of SC adipose tissues of tolylsam‐treated mice ( P  < 0.001). Thus, the relatively gelatinase‐specific MMP inhibitor tolylsam has the potential to affect fat tissue growth in obese mice.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here